Patients with Myelodysplastic Syndromes Display Several T-cell Expansions, Which Are Mostly Polyclonal in the CD4(+) Subset and Oligoclonal in the CD8(+) Subset
Overview
Authors
Affiliations
Objective: Immune dysregulation plays a role in the pathophysiology of myelodysplastic syndromes (MDS), as T-cell clones seem to be involved in the inhibition of hematopoietic precursors. The purpose of this study was to analyze the T-cell receptor (TCR) repertoire of MDS patients, focusing on the third complementarity determining region (CDR3) pattern of their CD4(+) and CD8(+) lymphocyte expansions.
Materials And Methods: The study involved 30 patients and 15 age-matched controls. The beta-variable (betaV) subfamily flow-cytometry analysis was performed on peripheral CD4(+) and CD8(+) T-cells. Spectratyping TCR-CDR3 analysis was carried out on isolated helper and cytotoxic T lymphocytes after immunomagnetic separation and reverse-transcriptase polymerase chain reaction.
Results: We first identified by flow cytometry an increased frequency of expanded betaVs in both CD4(+) and CD8(+) T-cells in MDS patients. We then showed, by spectratyping, that the CDR3 profile was mostly Gaussian in their CD4(+) T cells, whereas CD8(+) T cells usually showed skewed or oligoclonal CDR3 regions. When we compared spectratyping and flow-cytometry findings in each patient, we showed that most CD4(+) lymphocyte expansions detected by flow cytometry had Gaussian CDR3 profiles, whereas most CD8(+) expansions were oligoclonal.
Conclusion: We confirm that in MDS patients the TCR-betaV repertoire is overall extremely contracted, especially in cytotoxic T cells. This pattern is mainly determined by selective proliferations of both helper and cytotoxic T cells, which are, however, mostly polyclonal in the former and oligoclonal in the latter. Such a difference, possibly related to the different human leukocyte antigen restriction, could reflect the selective involvement of cytotoxic T cells either in the anti-tumor immune surveillance or in an autoreactive aggression toward hematopoietic precursors.
The Emerging Role of CD8 T Cells in Shaping Treatment Outcomes of Patients with MDS and AML.
Tasis A, Spyropoulos T, Mitroulis I Cancers (Basel). 2025; 17(5).
PMID: 40075597 PMC: 11898900. DOI: 10.3390/cancers17050749.
Barakos G, Georgoulis V, Koumpis E, Hatzimichael E Diseases. 2025; 13(1).
PMID: 39851483 PMC: 11765071. DOI: 10.3390/diseases13010019.
Zhang H, Zhang L, Liang X, Zhang L, Ma B, Li Y Hereditas. 2024; 161(1):38.
PMID: 39407301 PMC: 11481600. DOI: 10.1186/s41065-024-00335-x.
Shen J, Senes F, Wen X, Monti P, Lin S, Pinna C Immunol Res. 2024; 72(6):1470-1478.
PMID: 39316338 PMC: 11618177. DOI: 10.1007/s12026-024-09546-w.
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Tentori C, Zhao L, Tinterri B, Strange K, Zoldan K, Dimopoulos K Hemasphere. 2024; 8(5):e64.
PMID: 38756352 PMC: 11096644. DOI: 10.1002/hem3.64.